Product Code Database
Recipharm is a leading global Contract Development and Manufacturing Organisation (CDMO), employing 5,200 people and operating in over a hundred markets worldwide.
Recipharm offers pharmaceutical manufacturing services across various dosage forms, including sterile fill & finish, oral solid dosage, and biologics. Additionally, they provide clinical trial material development and manufacturing services, as well as pharmaceutical product development.
Recipharm manufactures several hundred different products for customers ranging from large pharmaceutical companies to smaller research and development firms.
In 1997, Recip was believed to be the first pharmaceutical company in the world to certify its entire operations according to the ISO 14001 environmental management system. From 1998, the company began to grow by acquiring facilities in Sweden. The brand name “Recipharm” was established in 2001 for the growing contract manufacturing part of Recip's business. In 2007, the Recip part of the business and the company's own portfolio were divested to Meda AB.
Recipharm became a public listed company on Nasdaq Stockholm in 2014. Between 2014 and 2019, Recipharm's sales grew by an average of more than 30 per cent annually, including a combination of internal growth and acquisitions. In 2020, Recipharm completed its largest acquisition to date. The £505 million takeover of UK-based Consort Medical added around 2,000 employees and ten European facilities to the company, as well as new device capabilities.
In February 2021, Private equity firm EQT AB acquired Recipharm for $2.1 billion. In March 2021, Mark Funk joined Recipharm as CEO, replacing Thomas Eldered who remains on the board of directors.
|
|
